Literature DB >> 19806170

Prostate cancer: Optimizing the duration of androgen deprivation therapy.

Eric M Horwitz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19806170     DOI： 10.1038/nrurol.2009.194

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

1.  Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

Authors:  Miljenko V Pilepich; Kathryn Winter; Colleen A Lawton; Robert E Krisch; Harvey B Wolkov; Benjamin Movsas; Eugen B Hug; Sucha O Asbell; David Grignon
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-04-01       Impact factor: 7.038

2.  Localized advanced carcinoma of the prostate: radiation therapy versus hormonal therapy.

Authors:  B van der Werf-Messing; V Sourek-Zikova; D I Blonk
Journal:  Int J Radiat Oncol Biol Phys       Date:  1976 Nov-Dec       Impact factor: 7.038

3.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.

Authors:  M Bolla; D Gonzalez; P Warde; J B Dubois; R O Mirimanoff; G Storme; J Bernier; A Kuten; C Sternberg; T Gil; L Collette; M Pierart
Journal:  N Engl J Med       Date:  1997-07-31       Impact factor: 91.245

4.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

5.  Duration of androgen suppression in the treatment of prostate cancer.

Authors:  Michel Bolla; Theodorus M de Reijke; Geertjan Van Tienhoven; Alphonsus C M Van den Bergh; Jorg Oddens; Philip M P Poortmans; Eliahu Gez; Paul Kil; Atif Akdas; Guy Soete; Oleg Kariakine; Elsbietha M van der Steen-Banasik; Elena Musat; Marianne Piérart; Murielle E Mauer; Laurence Collette
Journal:  N Engl J Med       Date:  2009-06-11       Impact factor: 91.245

6.  Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study.

Authors:  G K Zagars; D E Johnson; A C von Eschenbach; D H Hussey
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-06       Impact factor: 7.038

7.  Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

Authors:  Mack Roach; Kyounghwa Bae; Joycelyn Speight; Harvey B Wolkov; Phillip Rubin; R Jeffrey Lee; Colleen Lawton; Richard Valicenti; David Grignon; Miljenko V Pilepich
Journal:  J Clin Oncol       Date:  2008-01-02       Impact factor: 44.544

8.  Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.

Authors:  Eric M Horwitz; Kyounghwa Bae; Gerald E Hanks; Arthur Porter; David J Grignon; Harmar D Brereton; Varagur Venkatesan; Colleen A Lawton; Seth A Rosenthal; Howard M Sandler; William U Shipley
Journal:  J Clin Oncol       Date:  2008-04-14       Impact factor: 44.544

9.  Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

Authors:  Gerald E Hanks; Thomas F Pajak; Arthur Porter; David Grignon; Harmart Brereton; Varagur Venkatesan; Eric M Horwitz; Colleen Lawton; Seth A Rosenthal; Howard M Sandler; William U Shipley
Journal:  J Clin Oncol       Date:  2003-11-01       Impact factor: 44.544
  9 in total
  1 in total

1.  Inherited Variants in Wnt Pathway Genes Influence Outcomes of Prostate Cancer Patients Receiving Androgen Deprivation Therapy.

Authors:  Jiun-Hung Geng; Victor C Lin; Chia-Cheng Yu; Chao-Yuan Huang; Hsin-Ling Yin; Ta-Yuan Chang; Te-Ling Lu; Shu-Pin Huang; Bo-Ying Bao
Journal:  Int J Mol Sci       Date:  2016-11-26       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.